Galectin Therapeutics Inc. (GALT) Friday reported second quarter net loss to common shares of $3.0 million or $0.19 per share, compared with a net loss of $3.9 million or $0.34 per share last year.
Research and development expense for the quarter was $1.2 million, compared with $1.3 million a year ago. Other expenses decreased to $1.5 million from $1.7 million in the prior year.
The company did not record any revenues for the quarter, as in the prior year.
For comments and feedback: editorial@rttnews.com